CAPRICOR THERAP. DL-001
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more
CAPRICOR THERAP. DL-001 (4LN2) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CAPRICOR THERAP. DL-001 (4LN2) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CAPRICOR THERAP. DL-001 - Net Assets Trend (None–None)
This chart illustrates how CAPRICOR THERAP. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CAPRICOR THERAP. DL-001 (None–None)
The table below shows the annual net assets of CAPRICOR THERAP. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CAPRICOR THERAP. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CAPRICOR THERAP. DL-001 Competitors by Market Cap
The table below lists competitors of CAPRICOR THERAP. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing VRV Software Corp Ltd
SHE:300352
|
$1.05 Billion |
|
Hanwha Investment&Securities Co Ltd
KO:003530
|
$1.05 Billion |
|
Precinct Properties New Zealand Limited
PINK:AOTUF
|
$1.05 Billion |
|
Taiji Computer Corp Ltd
SHE:002368
|
$1.05 Billion |
|
TD Power Systems Limited
NSE:TDPOWERSYS
|
$1.05 Billion |
|
King’s Town Bank
TW:2809
|
$1.04 Billion |
|
Qingdao Port International Co. Ltd
PINK:QNDPF
|
$1.04 Billion |
|
E-Mart
KO:139480
|
$1.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CAPRICOR THERAP. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CAPRICOR THERAP. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CAPRICOR THERAP. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CAPRICOR THERAP. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CAPRICOR THERAP. DL-001 (4LN2) | €- | N/A | N/A | $1.05 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |